Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow
We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
New cancer vaccine shows promising results for certain patients
There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for ...
A New Mexico District Says It’s Reduced Harsh Discipline of Native Students. But the Data Provided Is Incomplete.
Following an investigation by New Mexico In Depth and ProPublica, Gallup-McKinley County says it cut down on long-term ...
Nature1d
Dozens of new obesity drugs are coming: these are the ones to watch
Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...
verywellhealth6d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer Type
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Updated drug information handout outdoes FDA's version in clinical trial
A clinical trial comparing a one-page medication handout proposed by the U.S. Food and Drug Administration (FDA) with an ...
The American Journal of Managed Care6d
Dr Jeff Stark: New Bimzelx Dose Offers Simplicity and Choice
On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.